Foreign Direct are evolving, with significant changes in the U.S., Canada, and the Netherlands. In the U.S., psychedelics like psilocybin remain Schedule I substances, but recent state-level reforms, such as in Oregon and Colorado, and FDA designations for psilocybin and MDMA therapies, signal a shift towards broader medical acceptance.
In Canada, most psychedelics are classified as illegal, but Health Canada's Special Access Program allows doctors to request psilocybin for patients with serious conditions, and provinces like British Columbia are leading efforts in psychedelic-assisted therapy.
The Netherlands takes a unique approach, where psilocybin truffles are legal and sold in smart shops, while psilocybin mushrooms remain prohibited. The country is also a hub for research and psychedelic retreats, with growing interest in their medical use.
